GSK Files For Japan Approval Of LABA/LAMA Drug For COPD Treatment
This article was originally published in PharmAsia News
Executive Summary
GlaxoSmithKline has filed for the approval in Japan of its combination drug containing the long-acting muscarinic antagonist meclidinium and the long-acting β2-agonist vilanterol for the treatment of chronic obstructive pulmonary disease, the company said April 22.
You may also be interested in...
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.